Human mucopolysaccharidosis VII (MPS VII, Sly syndrome) results from a deficiency of ␤-glucuronidase (GUS) and has been associated with a wide range in severity of clinical manifestations. To study missense mutant models of murine MPS VII with phenotypes of varying severity, we used targeted mutagenesis to produce E536A and E536Q, corresponding to active-site nucleophile replacements E540A and E540Q in human GUS, and L175F, corresponding to the most common human mutation, L176F. The E536A mouse had no GUS activity in any tissue and displayed a severe phenotype like that of the originally described MPS VII mice carrying a deletion mutation (gus mps/mps ). E536Q and L175F mice had low levels of residual activity and milder phenotypes. All three mutant MPS models showed progressive lysosomal storage in many tissues but had different rates of accumulation. The amount of urinary glycosaminoglycan excretion paralleled the clinical severity, with urinary glycosaminoglycans remarkably higher in E536A mice than in E536Q or L175F mice. Molecular analysis showed that the Gus mRNA levels were quantitatively similar in the three mutant mouse strains and normal mice. These mouse models, which mimic different clinical phenotypes of human MPS VII, should be useful in studying pathogenesis and also provide useful models for studying enzyme replacement therapy and targeted correction of missense mutations.
Human mucopolysaccharidosis VII (MPS VII, Sly syndrome) results from a deficiency of ␤-glucuronidase (GUS) and has been associated with a wide range in severity of clinical manifestations. To study missense mutant models of murine MPS VII with phenotypes of varying severity, we used targeted mutagenesis to produce E536A and E536Q, corresponding to active-site nucleophile replacements E540A and E540Q in human GUS, and L175F, corresponding to the most common human mutation, L176F. The E536A mouse had no GUS activity in any tissue and displayed a severe phenotype like that of the originally described MPS VII mice carrying a deletion mutation (gus mps/mps ). E536Q and L175F mice had low levels of residual activity and milder phenotypes. All three mutant MPS models showed progressive lysosomal storage in many tissues but had different rates of accumulation. The amount of urinary glycosaminoglycan excretion paralleled the clinical severity, with urinary glycosaminoglycans remarkably higher in E536A mice than in E536Q or L175F mice. Molecular analysis showed that the Gus mRNA levels were quantitatively similar in the three mutant mouse strains and normal mice. These mouse models, which mimic different clinical phenotypes of human MPS VII, should be useful in studying pathogenesis and also provide useful models for studying enzyme replacement therapy and targeted correction of missense mutations.
knock-in mice ͉ point mutation ͉ Cre-loxP M ucopolysaccharidosis type VII (MPS VII or Sly syndrome) is a mucopolysaccharide storage disease resulting from a deficiency of ␤-glucuronidase (GUS, EC 3.2.1.31) (1). In MPS VII, chondroitin sulfate, dermatan sulfate, and heparan sulfate are only partially degraded and accumulate in the lysosomes of many tissues, leading to cellular and organ dysfunction. MPS VII has also been reported in canine, murine, and feline species. Human patients with MPS VII display a wide range of clinical severity, and Ͼ45 different mutations have been found in the GUS gene (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) . Around 90% of these are point mutations. L176F accounts for Ϸ20% of mutant alleles. This mutation was first identified in a Mennonite family (7) , and then observed in other populations. Most patients homozygous for L176F have a mild phenotype. This mutation is interesting because cells from L176F patients have Ͻ1% of normal GUS activity, but expression of the L176F cDNA in COS cells produced nearly as much enzyme activity as the WT control cDNA (7) .
Characterization of human GUS protein by x-ray crystallography and homology comparisons among several species suggested R382, E451, and E540 as active-site residues (14) . E540 was identified as the active-site nucleophile of the human enzyme (15, 16) . Recombinant E540A human GUS had no catalytic activity, but the E540Q GUS showed 0.3% of WT activity (16) . One severely affected MPS VII patient with a null mutation at this residue, E540K, has been identified (S.T. and W.S.S., unpublished observation).
The original MPS VII (gus mps/mps ) mice with a 1-bp deletion in exon 10 have morphologic, genetic, and biochemical characteristics similar to those of MPS VII patients (17, 18) . The features of this murine model, with a known and uniform genetic constitution, made it attractive for studying experimental therapies for lysosomal storage disorders. Missense mutant mouse models allow functional analysis of specific amino acid replacements. We used targeted mutagenesis to produce three such models of MPS VII: E536A, E536Q, and L175F. The E536 residue in exon 10 was selected because it was implicated as an active-site nucleophile (15, 16) . Differences in residual activity between recombinant E536A and E536Q were noted in vitro and raised the possibility that the E536Q mutation might provide a milder form of MPS VII than E536A (16) . The L175F mutation was selected because the homologous human mutation, L176F, was the most prevalent mutation among MPS VII patients and was usually associated with a mild phenotype.
These mice provided the opportunity to explore (i) how the residual enzyme activity level measured in vitro correlates with phenotype, (ii) how glycosaminoglycan (GAG) storage correlates with the individual mutations, and (iii) how phenotypes in mild and severe murine models correlate with those of human patients who have MPS VII caused by similar mutations.
Materials and Methods
Site-Directed Mutagenesis and Targeting Vector Construction. Recombinant phage clones containing the Gus locus were isolated from an SvJ129 mouse genomic DNA library (Stratagene). The 5Ј 8.5-kb fragment and 3Ј 3.9-kb fragment of the murine Gus gene (containing exons 1-9 and exon 10, respectively) were subcloned into the pBS vector. The mutations (underlined) were introduced into the appropriate fragments by using the following mutagenic primers: for E536A in exon 10, 5Ј-CCGATTATC-CAGAGCGCGTATGGAGCAGACGCAATC-3Ј; for E536Q in exon 10, 5Ј-CCGATTATCCAGAGCCAGTACGGAGCA-GACGCAATC-3Ј; and for L175F in exon 2, 5Ј-ATCACGAT-TGCCATTAACAACACATTTACCCCTCATACC-3Ј. The E536A, E536Q, or L175F point mutation and the indicated additional base changes created new BstUI, RsaI, or MseI restriction sites, respectively. The presence of each point mutation was confirmed by sequence analysis of exons 1-10.
The pPNT-lox vector, generously provided by Shinji Hirotsune (National Human Genome Research Institute, National Institutes of Health, Bethesda), was modified to contain a 3Ј phosphoglycerine kinase neo r cassette flanked by loxP sites and a 5Ј thymidine kinase (TK) cassette and was named pPNT-loxP2. The 3Ј 3.9-kb XhoI-NotI fragment of the murine Gus gene was introduced at NotI͞XhoI-digested sites of the pPNT-loxP2 vecAbbreviations: MPS VII, mucopolysaccharidosis type VII; GAG, glycosaminoglycan; GUS, ␤-glucuronidase; ES, embryonic stem. § To whom correspondence should be addressed. E-mail: slyws@slu.edu.
tor. Next, the 8.5-kb XhoI-SalI fragment containing exons 1-9 was added between the TK and neo r genes to create the complete targeting vector. The final construct contained 8.5 and 3.9 kb of 5Ј and 3Ј homology of the Gus gene, respectively, with each point mutation (Fig. 1 ). , which are published as supporting information on the PNAS web site, www.pnas.org. Two independent, targeted ES clones were injected into C57BL͞6J blastocysts, and chimeric males were backcrossed for germ-line transmission to C57BL͞6J females. The F 1 mice were crossed with mice expressing Cre enzyme to remove the neo r gene (19) . The resultant neo-excised heterozygous mice were mated to produce homozygous mutant mice. Genotyping was performed by PCR analysis of DNA obtained by tail biopsies at 10 days and confirmed by assaying the GUS activity. The resultant homozygous mice with E536A, E536Q, or L175F point mutations were named Gus 
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Northern Blot Analysis and RT-PCR. Total cellular RNA was isolated from tissues of homozygous MPS VII mutants, heterozygotes, and WT mice by using a guanidinium͞phenol solution (RNAStat-60, Tel-Test, Friendswood, TX). Twenty micrograms of RNA from each source was denatured in formaldehydecontaining buffer and electrophoresed. The RNA was transferred to nylon membranes (Amersham Pharmacia) and prehybridized at 65°C. Blots were hybridized overnight at 65°C with 32 P-labeled mouse Gus cDNA probes. mRNA was also analyzed by RT-PCR followed by diagnostic restriction enzyme digestion and analysis on agarose gels (see Supporting Methods and Fig. 6 , which are published as supporting information on the PNAS web site).
Western Blot Analysis. Tissues were dissected and homogenized immediately (by a Brinkmann Polytron homogenizer for 30 sec at 4°C) in 5 vol of homogenization buffer (25 mM Tris⅐HCl, pH 7.2͞140 mM NaCl͞1 mM PMSF). Samples containing 20 g of protein were analyzed by SDS͞PAGE under reducing conditions as described (20) . The polypeptides were electronically transferred to Immobilon-P membranes (Millipore). After transblotting, the polypeptides were immunostained by using polyclonal rabbit anti-mouse GUS antibody followed by incubation with goat anti-rabbit IgG (Sigma) coupled with peroxidase. The peroxidase activity was visualized by using a chemiluminescent substrate.
Lysosomal Enzyme Assays. GUS and two other lysosomal enzymes, ␣-galactosidase and ␤-hexosaminidase, were assayed fluorometrically by using 4-methylumbelliferyl substrates as described (21) (22) (23) ] extracts for 24 h. Assays of other lysosomal enzymes were incubated for 1 h. Units were nmol hydrolyzed per h, and activity was expressed as units͞mg protein, as determined by micro-Lowry assay.
Analysis of GAGs.
To determine the g of GAGs per mg of urinary creatinine, we measured urine with 1,9-dimethylmethylene blue (24) (25) (26) . Creatinine was measured by mixing 10 l of a 10-fold diluted urine sample with 50 l of saturated picric acid (Sigma) and 50 l of 0.2 M NaOH. Absorbance at 490 nm was read after 20 min and compared with a standard.
Pathology. Multiple tissues from six of each of the MPS VII mouse strains [Gus tm(E536A)Sly , Gus tm(E536Q)Sly
, and Gus tm(L175F)Sly ], 2-6 months of age, were studied morphologically as described (27) . Tissues were evaluated for the extent of lysosomal storage. Alterations in the three strains were compared with each other and with the original MPS VII model (gus mps/mps ). Long bones from the Gus tm(E536A)Sly , Gus tm(E536Q)Sly , and Gus tm(L175F)Sly mice were radiographed as described (27) .
Results
Generation of Gus tm(E536A)Sly , Gus tm(E536Q)Sly , and Gus tm(L175F)Sly
Knock-In Mice. To introduce each point mutation in the Gus gene in mouse ES cells, we designed a targeting vector with a total of 12.4 kb of homologous genomic sequence (Fig. 1) . The mutation was cotransferred with neo flanked by two loxP sites through homologous recombination in ES cells. After selection with G418 and ganciclovir, doubly resistant clones were screened for homologous recombination by PCR followed by Southern blotting with a 3Ј external probe. Of 96 clones screened for each mutation by PCR, 20 E536A, 20 E536Q, and 10 L175F were homologous recombinant clones. The presence of the introduced point mutation in the targeted clones was analyzed by PCR amplification followed by restriction enzyme digestion (see Supporting Methods and Fig. 6 ). Thirteen of 20 (65%) clones contained the E536A mutation (BstUI digestion), 14 of 20 (70%) clones contained the E536Q mutation (RsaI digestion), and three of 10 (30%) clones contained the L175F mutation (MseI digestion).
Targeted ES cells containing each mutant allele were injected into C57BL͞6J blastocysts, and chimeric males were obtained, followed by germ-line transmission of the mutant allele (F 1 ). F 1 offspring heterozygous for each of the three mutations were independently intercrossed with C57BL͞6J mice to generate F 2 homozygous mice that were 129͞Sv ϫ C57BL͞6J hybrids. This strategy generated mice heterozygous for the mutation, with the expected Mendelian segregation (WT and mutant, 1:1) at birth.
Phenotype of the MPS VII Missense Mutants. Homozygous E536A MPS VII mice, herein referred to as Gus tm(E536A)Sly mice, were not distinguishable phenotypically from heterozygous and homozygous WT littermates at birth but could easily be identified by the time of weaning. They had shortened faces and were slightly smaller. As they aged, their growth retardation, shortened extremities, and facial dysmorphism became more prominent ( Fig. 2A) 
, and Gus tm(L175F)Sly
mice were maintained by brother-sister matings, genotyped by PCR analysis of genomic DNA, and confirmed by enzymatic analysis of extracts of tail samples for GUS activity. Homozygous offspring from these colonies were analyzed for biochemical, morphological, and histopathological phenotypes.
In more than 100 offspring from each mutant line, crosses between heterozygotes produced progeny with a distribution at weaning of 27% ϩ͞ϩ, 59% ϩ͞Ϫ, and 14% Ϫ͞Ϫ for the Gus tm(E536A)Sly mice; 26% ϩ͞ϩ, 51% ϩ͞Ϫ, and 23% Ϫ͞Ϫ for the Gus
tm(E536Q)Sly
; and 24% ϩ͞ϩ, 54% ϩ͞Ϫ, and 22% Ϫ͞Ϫ MPS VII mice (5) (Fig. 3A) . Both the Gus tm(E536Q)Sly and Gus tm(L175F)Sly mice had residual enzyme activity, between 0.1% and 0.7% of normal controls, depending on the tissue measured. The GUS activities in the Gus tm(E536Q)Sly and Gus tm(L175F)Sly mice were 3-to 30-fold higher than the background levels found in Gus tm(E536A)Sly mice. Secondary elevations of other lysosomal enzymes, including ␣-galactosidase and ␤-hexosaminidase, were noted in most of the tissues of 3-to 6-month-old mice (Fig. 3B) . In Gus tm(E536A)Sly mice, the ␣-galactosidase level was 2-to 10-fold higher than that of normal controls. Secondary elevation of ␣-galactosidase and ␤-hexosaminidase enzyme activities in tissues tended to increase as the mice aged.
Accumulation of Urinary GAGs. Urine was collected from Gus tm(E536A)Sly , Gus tm(E536Q) Sly 
, Gus tm(L175F)Sly
, and WT mice. The level of GAGs in urine from Gus tm(E536A)Sly mice was 10-fold higher than that in normal control mice, whereas the levels from Gus tm(E536Q)Sly and Gus tm(L175F)Sly mice were increased 3-fold (Fig. 3C ). There were no overlapping values between those three mutants and the WT mice.
Murine Gus mRNA Transcript and Expression of Murine GUS Protein.
Northern blot analyses on total RNA isolated from liver of (Fig. 4) and also in spleen, neurons, and retinal pigment epithelium (not shown). The amount and extent of storage was similar to that of the original MPS VII gus mps/mps mice (17, 27) . In the Gus tm(L175F)Sly mice, storage was similar in distribution although less extensive. There was very little storage apparent in the brain and spleen in most of the Gus tm(L175F)Sly mice, correlating with the presence of residual GUS activity in these tissues. Gus tm(E536Q)Sly mice had much less storage in renal tubular epithelial cells and hepatocytes than the other two strains, which correlated with their higher residual levels of GUS in these two tissues. The bone, articular surface, and synovium of the limb joints also differed in severity of histopathology among the Gus tm(E536A)Sly , Gus tm(L175F)Sly , and Gus tm(E536Q)Sly mice (see Fig. 7 , which is published as supporting information on the PNAS web site).
Discussion
The original gus mps/mps MPS VII mouse has a 1-bp deletion in exon 10 and produces only 1͞200 of normal levels of Gus mRNA (17, 18, 27) . These mice have many biochemical, pathological, and phenotypic similarities with MPS VII patients with a severe phenotype. The majority of patients with human MPS VII have different missense mutations that contribute to the broad range of clinical phenotypes. E540 has been identified as the active-site nucleophile of the human GUS gene (15, 16) . For this reason, we targeted E536 (the residue homologous with E540 in human GUS) to produce a missense mutation conferring a null MPS VII mouse phenotype caused by an enzymatically inactive GUS. mice shows how sensitive this enzyme is as a secondary marker of GAG accumulation. It is for this reason that ␣-galactosidase is a valuable marker for following the response to enzyme replacement therapy (29) .
We have not identified the mechanism underlying the residual GUS activity produced by the E536Q but not the E536A knock-in allele. In vitro expression studies also showed that cells expressing human E540Q (or mouse E536Q) had detectable levels of GUS activity (16) . Several factors could explain this residual activity. Glutamate (E) and glutamine (Q) residues are similar amino acids and differ only in one additional amino group on glutamine. The chemical difference, including composition, polarity, and molecular volume, between E and Q is minimal, whereas the chemical difference between E and A (alanine) is greater (30) . Possibly, Q has a low level of activity as a nucleophile (16) , whereas A has none. Also, enzymatic or nonenzymatic conversion of Q536 to E536 by in vivo deamidation could also contribute (31) . The higher levels of E536Q activity in liver and kidney compared with other tissues favor this explanation.
The L175F mutation in murine MPS VII led to a milder phenotype, as has been seen with many human MPS VII patients homozygous for the orthologous (L176F) mutation. In vitro expression studies showed that overexpression of GUS cDNA containing the L176F mutation resulted in 60 -80% of the GUS activity of the WT cDNA (7) . However, the fibroblasts from human MPS VII patients homozygous for the L176F mutation revealed only 0.5-2% of enzyme activity. The discrepancy between the MPS phenotype, which was consistent with the low level of activity in cells from patients, and the much-higher-than-expected level of GUS activity generated by transient expression has been seen in other mutations of the human GUS gene (4, 5) . However, the L176F mutation is the most extreme example. It has been suggested that overexpression of mutant monomers could, by mass action, drive the folding reaction or the assembly into tetramers, which achieve a more stable conformation once formed (7). Whether one can
